PSNL
PersonalisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
If Personalis secures multiple recurring contracts and demonstrates improving gross margins, revenue growth could justify premium valuation and a move above $1.30 (driven by multiple expansion and improved cash metrics).
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.7.
What can break
Continued weak revenue, high cash burn, or an unfavorable financing would compress equity value toward or below $0.45; biotech/diagnostics microcaps often trade near liquidation or distressed levels during equity raises.
Momentum
99
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $1.30 · Bear $0.45
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $13.88
Why
Momentum99 · Δ7d +0.7
Value41 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+0.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 99.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.4B
Beta
1.99
Shares Out
104.72M
P/E (TTM) · Derived
-14.6
P/S (TTM)
10.31
P/FCF (TTM) · Derived
-14.79
Rev YoY
-24.9%
EPS YoY
+60.0%
Gross Margin
+13.7%
Op Margin
-117.1%
Net Debt
-$199.14M
Current Ratio
6.57
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology